Medical Genetics in Ophthalmology: Through the Lens of Genetics-Informed Therapies OnDemand-Joint Closing – The Evolution of Gene Therapy: Milestones, Challenges, and Future Directions

Video Transcription

Video Summary

Dr. Eric, with extensive training in biochemistry and ophthalmology, leads the Ocular Genomics Institute at Harvard, focusing on inherited eye diseases through precision medicine, molecular studies, and clinical trials. His pioneering work includes the first in vivo CRISPR trial targeting the CEP290 gene for inherited retinal degeneration (IRD). He discussed the successes and challenges of gene therapies, highlighting the evolution from approved viral vector-based treatments (like AAV and antisense oligonucleotides) to emerging gene editing technologies including base and prime editing. He cited examples such as spinal muscular atrophy treatments and CRISPR-based sickle cell therapy, illustrating how genetic medicines are transforming rare disease care.<br /><br />A central theme was the complexity of Mendelian diseases. Contrary to the classical view of single-gene deterministic inheritance, Dr. Eric’s research using large biobank genomic and health data revealed unexpectedly low penetrance (~10-30%) of known IRD gene variants among adults. This challenges assumptions about genetic causality, suggesting modifier genes and environmental factors contribute to disease expression and therapy response. He advocated for refining genetic definitions and developing better clinical endpoints and delivery methods to overcome inflammation and scalability issues.<br /><br />Dr. Eric emphasized the need for collaborative, large-scale population studies to identify genetic modifiers and optimize therapies, underscoring the evolving nature of interventional genetics. He also highlighted the FDA’s draft guidance supporting genetically informed targeted treatments, promising more efficient approvals in rare diseases.

Asset Subtitle

Eric Pierce, MD, PhD

Keywords

Ocular Genomics Institute

inherited eye diseases

precision medicine

CRISPR gene editing

CEP290 gene

retinal degeneration

gene therapy challenges

Mendelian disease complexity

genetic modifiers